Iorio Et Al J. Pharmacol. Exp. Ther. 258(1):118-123 SCH 23390 Potential SCH 39166 Antipsychotic, (1991).* |
Tedford Et Al Pschychopharmacology 113(2): 199-204 SCH 39166 Cond. Avoiding Behavior, (1993).* |
Tedford Et Al Drug Res. Dev. 26(4):389-403 SCH 39166 Cond. Avoid. Behavior, (1992).* |
Coffin Et Al J Neurochem. 57(6):2001-2010 SCH 39166 Antipsychotic, (1992).* |
McQuade Et Al Eur. J. Pharmacol. 215(1): 29-34 SCH 39166 Antipsychotic, (1992).* |
Coffin Et Al J. Neuro Chem. 57(6):2001-2010 SCH 39166 SCH170 Phroma, (1991).* |
Chipkin Et Al J. Pharmacol. Exp Ther. 247(3):1093-1102 SCH 39166 Antipsychotic, (1988).* |
J. Med. Chem. 38(21):4284-4293, (1995).* |
Gilbert Et Al Brain Res. Bull. 15(4): 385-389 SCH 23390 Reversed Anorexia, 1988.* |
Arnt Et Al Evr. J. Pharmacol. 133(2):137-145 SCH 23390 Blocks Sterotyped Behavior, 1987.* |
Delbs Et Al Neuroscience (Oxford) 39(1) : 59-67 SCH 23390 Antagonizes Stereotype Behavior, 1990.* |
Bruhwyler Et Al Pharmacol Biochem. Behav. 39(2) : 367-371 SCH 23390 Anxiolytic Against Anxiety, 1991.* |
Blaumonde Et Al Evr. J. Pharmacol. 216(2):157-165 SCH 23390 Antidepressant Forced of Swim Test, 1992.* |
Simon Et Al Pharmacol. Biochem. Behav 45(3): 685-690 SCH 23390 Antagonize Anxiety, 1993.* |
Rodgers Et Al Pharmacol. Biochem. Behav. 49(4); 985-995 SCH 23390 Anxiety Effect., 1994.* |
Harrison Et Al Psychopharmacology 133(4):329-342 SCH 23390 Blocks Impulse Behavior, 1997.* |
Woodskettelburger Et Al Exp. Opinion. Invest. Drugs 6(10):1369-1381 SCH 23390 Obsessive Compulsive, 1997.* |
Yeghiayian Et Al Pharma Cology Biochemistry Behav. 5(2/3):493-501 SCH 23390 Obsession, 1995.* |
Hart Braves Et Al Psychopharmacology 90(3):355-367 SCH 23390 Compuls. Behav. Blocked, 1986.* |
Balthazart Et Al Physiol. & Behav. 62(3);571-580 SCH 23390 Male Sexual Behavior Appetitive & Consummate Block, 1997.* |
Zarrindast Et Al Evr. J. Pharmacol. 321(21):157-162 SCH 23390 Anoroxia Induced., 1993.* |
Rowlott Et Al Synadse 14(2):160-168 SCH 23390 Behavior Senstise, 1993.* |
Zarrindast Et Al Gen. Pharmacol. 22(6): 1011-1016 SCH 23390 Induces Anorexia, 1991.* |
Chemical Abstracts, AN=130:46933.XP002107374, Peacock et al., “D-1 Antagonists in Animal Models and in Schizophrenia: Potential Antipsychotic Effects and Extrapyramidal Side Effects.” |
Balthazart et al., “Differential Effects of D1 and D2 Dopamine-Receptor Agonists and Antagonists on Appetitive and Consumatory Aspects of Male Sexual Behavior in Japanese Quail”—Physiol. Behav., 62: Issue 3, 571-589, 1997. |
Acri, J.B., et al., Behavioral Effects and Dopamine Antagonists Properties of N-Alkylaminobenzazepines, Drug Development Research, 37: 39-47, 1996. |
Hollander, Eric, et al., New Frontiers in OCD Spectrum Research for Psychiatry and Primary Care, The Journal of Clinical Psychiatry, 57: 3-87, 1996. |
Shah, Jamshed H., et al., (±)-(N-Alkylamino) benzazepine Analogs: Novel Dopamine D1 Receptor Antagonists, J. Med., Chem., 38: 4284-4293, 1995. |
Gnanalingham, Kanna K., et al., Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease—the differential effects of D1 dopamine antagonists in the primate, Psychopharmacology, 117: 403-412, 1995. |
Cook, Edwin H., Jr., et al., Receptor Inhibition by Immunoglobulins: Specific Inhibition by Autistic Children, Their Relatives, and Control Subjects, Journal of Autism and Developmental Disorders, 23: No. 1, 1993. |
Coffin, Vicki L., et al., SCH 39166, A Potential Antipsychotic Drug, Does Not Evoke Movement Disorders in Cebus Monkeys, Neurochem. Int., 20: 141S-145S, 1992. |
Criswell, Hugh E., et al., Pharmacologic Evaluation of SCH-39166, A-69024, NO-0756, and SCH-23390 in Neonatal-6-OHDA-Lesioned Rats, Neuropsychopharmacology, 7: No. 2, 95-102, 1992. |
McHugh, Daniel and Vicki Coffin, The reversal of extrapyramidal side effects with SCH 39166, a dopamine D1 receptor antagonist, European Journal of Pharmacology, 202: 133-134, 1991. |
Eric Hollander, M.D., Obsessive-Compulsive-Related Disorders, 1-17. |
Kerkman, Daniel J., et al., A-69024: a non-benzazepine antagonists with selectivity for the dopamine D-1 receptor, European Journal of Pharmacology, 166: 481-491, 1989. |
John L. Waddington, Therapeutic Potential of Selective D-1 Dopamine Receptor Agonists and Antagonists in Psychiatry and Neurology, Gen. Pharmac., 19:, No. 1, 55-60, 1988. |
Michèle Beaulieu, Clinical Importance of D-1 and D-2 Receptors, The Canadian Journal of Neurological Sciences, 14: 402-406, 1987. |
Gilbert et al., “Analysis of Dopamine D1 and D2 Receptor Involvement in D-and 1-Amphetamine-Induced Anorexia in Rats”, Brain Res. Bull., 15:, Issue 4, 385-398, 1985. |